Cancer onset and progression involves disruptions of complex networks of biomolecular interactions in cells, as a result of genomic and epigenomic aberrations. To achieve a deeper understanding of the genetic basis of cancer and to identify novel translational directions requires moving beyond detecting simple associations between genomic aberrations and clinical endpoints. However, little is known about how the states of disease-perturbed regulatory networks are altered by such aberrations, or how aberrations ultimately lead to cellular dysfunction. The goal of the Center for Systems Analysis of the Cancer Regulome is to address this challenge by developing and applying advanced algorithms and model-based approaches to enable the interpretation of TCGA data at the level of regulatory mechanisms;and to use such knowledge for enabling principled and systematic approaches for drug target discovery and therapeutic intervention in a clinically relevant manner. The Center will build three computational pipelines that will carry out integrated analyses of TCGA-derived high-throughput experimental data sets. These pipelines will: 1) identify potential mechanisms of genomic-transcriptomic regulation associated with specific cancers and clinical parameters;2) infer networks that explain cancer type-specific transcriptional profiles, and identify molecules that may be important control nodes in these networks as a means to prioritize drug targets for therapeutic intervention;and 3) compare cancer-associated features across all cancer types within TCGA to gain insight into the regulatory basis for cancer progression in different cancer types. The results of these pipelines will be rapidly disseminated through TCGA, together with visualization tools that facilitate the exploration and evaluation of each derived regulatory mechanism.
Cancer is a major cause of mortality and morbidity in the United States. Developing new therapies requires a deep understanding of the molecular basis of this complex genetic disease. Our integrated systems-level analysis of cancer onset and progression will map the molecular processes undertying cancer and identify potential novel drug targets for therapeutic intervention.
|Cherniack, Andrew D; Shen, Hui; Walter, Vonn et al. (2017) Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell 31:411-423|
|Cancer Genome Atlas Research Network. Electronic address: email@example.com; Cancer Genome Atlas Research Network (2017) Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171:950-965.e28|
|Robertson, A Gordon; Kim, Jaegil; Al-Ahmadie, Hikmat et al. (2017) Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171:540-556.e25|
|Cancer Genome Atlas Research Network; Albert Einstein College of Medicine; Analytical Biological Services et al. (2017) Integrated genomic and molecular characterization of cervical cancer. Nature 543:378-384|
|Fishbein, Lauren; Leshchiner, Ignaty; Walter, Vonn et al. (2017) Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell 31:181-193|
|Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency et al. (2017) Integrated genomic characterization of oesophageal carcinoma. Nature 541:169-175|
|Huo, Dezheng; Hu, Hai; Rhie, Suhn K et al. (2017) Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol 3:1654-1662|
|Robertson, A Gordon; Shih, Juliann; Yau, Christina et al. (2017) Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell 32:204-220.e15|
|Cancer Genome Atlas Research Network. Electronic address: firstname.lastname@example.org; Cancer Genome Atlas Research Network (2017) Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169:1327-1341.e23|
|Sun, Yan; Ji, Ping; Chen, Tao et al. (2017) MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. J Pathol 241:67-79|
Showing the most recent 10 out of 85 publications